Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), Reus, Spain.
Nutr Rev. 2019 Dec 1;77(12):845-864. doi: 10.1093/nutrit/nuz036.
The cardioprotective effects of the flavonoid hesperidin, which is present in citrus products, are controversial and unclear. This systematic review was conducted in accordance with the PRISMA 2015 guidelines.
To evaluate the current evidence from animal and human clinical studies and thus determine whether the consumption of hesperidin exerts beneficial effects on cardiovascular risk factors.
PICOS (Population, Intervention, Comparison, Outcome, and Study Design) criteria defined the research question. Searches of the PubMed and Cochrane Plus databases were conducted and studies that met the inclusion criteria and were published in English in the last 15 years were included.
The first author, year of publication, study design, characteristics of animals and humans, intervention groups, dose of hesperidin, route of administration, duration of the intervention, cardiovascular risk biomarkers assessed, and results observed were extracted from the included articles.
A total of 12 animal studies and 11 randomized clinical trials met the inclusion criteria. In the animal studies, the glucose, total and LDL cholesterol, and triglyceride levels decreased with chronic flavonoid consumption. In the human studies, endothelial function improved with flavonoid consumption, whereas no conclusive results were observed for the other biomarkers.
Animal studies have revealed that hesperidin and hesperetin consumption reduces glucose levels and various lipid profile parameters. However, a definitive conclusion cannot be drawn from the existing human clinical trials. Further research is needed to confirm whether the findings observed in animal models can also be observed in humans.
Prospero registration number CRD42018088942.
存在于柑橘类产品中的类黄酮橙皮苷具有心脏保护作用,但目前其作用效果仍存在争议,并不明确。本系统评价是按照 PRISMA 2015 指南进行的。
评估来自动物和人体临床研究的现有证据,从而确定橙皮苷的摄入是否对心血管风险因素有有益影响。
根据人群(Population)、干预措施(Intervention)、比较(Comparison)、结局(Outcome)和研究设计(Study Design)(PICOS)标准确定了研究问题。对 PubMed 和 Cochrane Plus 数据库进行了检索,纳入了符合纳入标准且在过去 15 年内以英文发表的研究。
从纳入的文章中提取第一作者、发表年份、研究设计、动物和人类特征、干预组、橙皮苷剂量、给药途径、干预持续时间、评估的心血管风险生物标志物以及观察到的结果。
共有 12 项动物研究和 11 项随机临床试验符合纳入标准。在动物研究中,慢性黄酮类化合物摄入可降低血糖、总胆固醇、LDL 胆固醇和甘油三酯水平。在人体研究中,黄酮类化合物摄入可改善内皮功能,但其他生物标志物的结果则不明确。
动物研究表明,橙皮苷和橙皮素的摄入可降低血糖水平和各种血脂参数。然而,现有的人体临床试验并不能得出明确的结论。需要进一步的研究来确认动物模型中观察到的结果是否也可以在人体中观察到。
Prospéro 注册号 CRD42018088942。